A pilot study of botulinum toxin A for headache in cervical dystonia

Headache

Volumn 45, Issue 8, 2005, Pages 1073-1077

  Ondo, William G ^a,d   Gollomp, Stephen ^b   Galvez Jimenez, Nestor ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DEPARTMENT OF COLORECTAL SURGERY   (United States)

^d NONE   (United States)

Author keywords

Botulinum toxin type A; Cervical dystonia; Cervicogenic; Headache

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; ATLANTOOCCIPITAL JOINT; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; DYSTONIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEALTH CENTER; HUMAN; MALE; MIGRAINE; NECK PAIN; PREVALENCE; PRIORITY JOURNAL; PTOSIS; RATING SCALE; WEAKNESS; CLINICAL TRIAL; HEADACHE AND FACIAL PAIN; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TORTICOLLIS; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXIN TYPE A; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; TORTICOLLIS; TREATMENT OUTCOME;

EID: 33644659492     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05190.x     Document Type: Article

References (15)

1. Brin M, Brashear A, Mordaunt J. Effect of botulinum toxin type A (BoNT-A) therapy on pain frequency and intensity in patients with cervical dystonia. Cephalalgia. 2003;23(7):743.
2. Galvez-Jimenez N, Lampuri C, Patino P, Hargreave MJ, Hanson MR. Dystonia and headaches: clinical features and response to botulinum toxin therapy. Adv Neurol. 2004;94:321-328.
3. Haldeman S, Dagenais S. Cervicogenic headaches. A critical review. Spine J. 2001;1(1):31-46.
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(suppl 1):1-150.
5. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40(8):1213-1218.
6. Truong DD, Duane DD, Jankovic J, Singer C, Comella CL. The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: results of the first US study. Mov Disord. 2002;17(suppl 5):S306
7. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701-707.
8. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40(6):445-450.
9. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004;24(1):60-65.
10. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40(3):231-236.
11. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy With Botulinum Toxins. New York: Marcel Dekker;1994:211-237.
12. Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963-974.
13. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107-114; discussion 174.
14. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470-482.
15. Relja MA, Klepac N. Botulinum toxin type-A as prophylactic treatment in chronic tension-type headache: long-term follow-up study. Neurology. 2001;56(suppl 3):A349-A350.